**MKV: Annual General Mandate 2024**

On April 20, 2024, Cai Lay Veterinary Pharmaceutical JSC announced General Mandate No. 02/2024/NQ/DHDCD-MKV as follows:

Article 1: Approve the Report of the Board of Directors in 2023;

* Revenue and other income VND 121,632,459,817
* Expenses: VND 113,880,611,147
* Profit before tax: VND 7,751,848,670
* Corporate income tax: VND 1,550,380,768
* Profit after tax: VND 6,201,467,902

Article 2: Approve the Report of the Supervisory Board in 2023

1. The Operation Scale of the Company:

The total enterprise value of the Company as of December 31, 2023 is: VND 98,325,982,520 (down VND 7,717,726,003 compared to that at the beginning of the year). In details:

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Target | Beginning of 2023 (January 1, 2023) | End of 2023 (December 31, 2023) |
| 1 | Cash and cash equivalents | 4,177,245,011 | 9,191,736,471 |
| 2 | Short-term financial investment | 6,000,000,000 | 6,000,000,000 |
| 3 | Short-term receivables | 25,093,746,293 | 33,106,484,040 |
| 4 | Inventory | 28,663,187,241 | 12,989,882,445 |
| 5 | Other short-term assets | 977,738,783 | 654,756,610 |
| 6 | Long-term receivables | 0 | 0 |
| 7  | Fixed assets | 40,312,089,646 | 34,359,037,259 |
| 8 | Long-term assets in process | 233,282,000 | 0 |
| 9 | Other long-term assets | 586,419,549 | 2,024,085,695 |
|  | Total | 106,043,708,523 | 98,325,982,520 |

1. Operating capital of the Company

Regular capital source to maintain the Company's operations as of December 31, 2023 is: VND 98,325,982,520; Including:

* Owners’ equity: VND 79,821,623,743
* Short-term loan: VND 0
* Long-term loan: VND 0
* Other capital: VND 18,504,358,777

(legal appropriations)

Compared to 2022, the Company's capital to maintain regular operations decreased by 7.3%, equivalent to a decrease of VND 7,717,726,003.

1. Production and business results in 2023
* Revenue and other income: VND 121,632,459,817
* Expenses: VND 113,880,611,147
* Profit before tax: VND 7,751,848,670
* Corporate income tax expense: VND 1,550,380,768
* Profit after tax is VND 6,201,467,902

Profit after tax in 2023 reached VND 6,201,467,902, an increase of VND 297,417,398 compared to that in 2022, profit after tax reached VND 5,904,050,504.

Article 3: Approve the Proposal on election of additional members of the Supervisory Board.

* Dismiss Mr. Than Van Dung from the position of member of the Supervisory Board of Cai Lay Veterinary Pharmaceutical JSC from April 20, 2024
* Appoint Ms. Phan Nguyen Truc My to the position of member of the Supervisory Board of Cai Lay Veterinary Pharmaceutical JSC from April 20, 2024.

Article 4: Approve the Proposal on the production and business plan for 2024.

The production and business plan for 2024 is as follows:

|  |  |
| --- | --- |
| Details | Plan for 2024 |
| Revenue | Rate |
| 1 | Revenue from goods sale | 148,300,000,000 | 100% |
| 2 | Profit before tax | 7,711,600,000 | 5.2% |

Article 5: Approve the Proposal of the Supervisory Board on selecting an audit company for the Financial Statements 2024.

The Supervisory Board of Cai Lay Veterinary Pharmaceutical JSC respectfully submits to the Annual General Meeting of Shareholders 2024 to consider and authorize the Board of Directors to select an audit company for the Financial Statements 2024.

Article 6: Approve the Proposal on the remuneration for the Board of Directors, the Supervisory Board and person in charge of corporate governance in 2024

Regular expenses of the Board of Directors, the Supervisory Board and person in charge of corporate governance are VND 264,000,000, accounting for 0.18% of revenue, including:

* Remuneration for the Board of Directors, the Supervisory Board and person in charge of corporate governance: VND 144,000,000
* Management costs and bonuses: VND 120,000,000

Remuneration for the Board of Directors, the Supervisory Board and person in charge of corporate governance in 2024 is as follows:

* Chair of the Board of Directors: VND 3,000,000/month
* Members of the Board of Directors, the Chief of the Supervisory Board: VND 2,000,000/month
* Chief of the Supervisory Board: VND 2,000,000/month
* Member of the Supervisory Board: VND 1,000,000/month
* Person in charge of Corporate Governance: VND 1,000,000/month

To be proactive in work, the Board of Directors proposes that the General Meeting of Shareholders authorize the Chair of the Board of Directors, on the basis of ensuring benefits for shareholders and the Company, to approve remuneration for each specific case for members of the Board of Directors, when members of the Board of Directors directly perform tasks that help promote the Company's production and business activities.

Article 7: Terms of enforcement

The General Meeting of Shareholders assigns the Board of Directors to implement the contents approved by the General Meeting of Shareholders at the General Meeting on the basis of ensuring the best interests of Shareholders and the Company, and complies with legal regulations and the Company’s Charter.

The General Meeting of Shareholders agrees to assign the Board of Directors and the Supervisory Board to implement the General Mandate unanimously approved by the General Meeting of Shareholders at the Annual Meeting on April 20, 2024 and report to the General Meeting of Shareholders in the following Meetings.

The full text of this General Mandate was approved at the General Meeting of Shareholders and takes effect from April 20, 2024.